Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Revenue (2020 - 2025)

Historic Revenue for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $133.0 million.

  • Mirum Pharmaceuticals' Revenue rose 4717.24% to $133.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $471.8 million, marking a year-over-year increase of 5366.48%. This contributed to the annual value of $336.9 million for FY2024, which is 8075.91% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Revenue stood at $133.0 million, which was up 4717.24% from $127.8 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Revenue high stood at $133.0 million for Q3 2025, and its period low was $3.1 million during Q4 2021.
  • Moreover, its 5-year median value for Revenue was $42.6 million (2023), whereas its average is $55.1 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 78929.25% in 2022, then soared by 4293.07% in 2024.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Revenue stood at $3.1 million in 2021, then surged by 789.29% to $27.9 million in 2022, then soared by 149.24% to $69.6 million in 2023, then soared by 42.93% to $99.4 million in 2024, then soared by 33.79% to $133.0 million in 2025.
  • Its Revenue stands at $133.0 million for Q3 2025, versus $127.8 million for Q2 2025 and $111.6 million for Q1 2025.